Exact Sciences Cor (EXAS) Stock Price, Quote & News

Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic,...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 608 284 5700

Website: www.exactsciences.com

Address:

5505 Endeavor Lane, Madison, United States

Peace2016 Oct. 27 at 4:36 AM

$EXAS we are up 5% in overnight market!!

0 · Reply

LiquidThetaLEAPS Oct. 27 at 3:47 AM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $EXAS Current Share Price: $64.64 Contracts: $EXAS January 15, 2027 $65 Calls Scale in: $13.50- $16.50 Scale out: $21.00-$27.00 Can Easily Capture: 60% ROI Blended DTE: 446 Days | Join Elites here: https://liquidtheta.com

0 · Reply

LiquidThetaLEAPS Oct. 26 at 5:47 AM

0 · Reply

Clargy Oct. 24 at 3:51 PM

$EXAS Eruption here soon

0 · Reply

LiquidThetaOptions Oct. 24 at 3:28 PM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $EXAS Current Share Price: $64.54 Contracts: $EXAS January 15, 2027 $65 Calls Scale in: $13.21- $16.14 Scale out: $20.54-$26.42 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

Kleeno Oct. 24 at 4:24 AM

$EXAS Kevin C took a CancerGuard test yesterday!!! https://www.linkedin.com/posts/kevin-conroy-850bb9_already-got-my-cancerguard-test-results-activity-7387191848395632640-heLX?utm_medium=ios_app&rcm=ACoAAANlOmEBNC_DxEf_8J4vtVfUZAEAlR6eE6s&utm_source=social_share_send&utm_campaign=copy_link

0 · Reply

cc10socr Oct. 24 at 2:24 AM

$EXAS just broke even on this, fuck it and sell?

1 · Reply

ManyThanks212 Oct. 23 at 5:32 PM

$EXAS

0 · Reply

Estimize Oct. 23 at 2:30 PM

Wall St is expecting -0.04 EPS for $EXAS Q3 [Reporting 11/03 AMC] http://www.estimize.com/intro/exas?chart=historical&metric_name=eps&utm_c

0 · Reply

Thelonius_Stonk Oct. 22 at 4:01 PM

$EXAS so strong

1 · Reply

Exact Sciences Presents New Findings at ACG 2025 Demonstrating How the Cologuard Test Helps Improve Adherence and Close Screening Gaps

Oct 8, 2025, 7:00 AM EDT - 19 days ago

Exact Sciences Schedules Third Quarter 2025 Earnings Call

Oct 7, 2025, 6:59 AM EDT - 20 days ago

New Study in Journal of the National Cancer Institute Finds Cologuard Plus™ Provides the Most Life-Years Gained with the Fewest Colonoscopies

Sep 25, 2025, 5:07 AM EDT - 4 weeks ago

Exact Sciences' Clear Expansion Path: Why Choose To Buy

Sep 22, 2025, 7:00 AM EDT - 5 weeks ago

Horror Icon Matthew Lillard and Exact Sciences Help Adults 45+ Conquer Fear and Get Screened for Colon Cancer with the Cologuard® Test

Sep 17, 2025, 8:30 AM EDT - 5 weeks ago

Healthmine and Exact Sciences Partner to Combine At-Home CRC Screening with Health Plan Incentives to Boost Preventive Care

Sep 15, 2025, 3:30 PM EDT - 5 weeks ago

Exact Sciences CEO on Launch of Multi-Cancer Blood Test

Sep 10, 2025, 6:30 AM EDT - 6 weeks ago

Exact Sciences Launches Cancerguard™, First-of-Its-Kind Multi-Cancer Early Detection Blood Test

Sep 9, 2025, 4:49 PM EDT - 6 weeks ago

Exact Sciences Corporation (EXAS) Presents At Baird 2025 Global Healthcare Conference (Transcript)

Sep 3, 2025, 4:14 PM EDT - 7 weeks ago

Exact Sciences Corporation (EXAS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Aug 22, 2025, 8:05 AM EDT - 2 months ago

Legal Win for Geneoscopy as Exact Sciences Withdraws Preliminary Injunction Against ColoSense®

Aug 19, 2025, 6:00 AM EDT - 2 months ago

Exact Sciences to Participate in September Investor Conferences

Aug 11, 2025, 8:01 AM EDT - 2 months ago

Top 3 Health Care Stocks That Are Preparing To Pump This Month

OM TNDM

Aug 7, 2025, 9:45 PM EDT - 2 months ago

Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025

ACLX BSX EW GH ISRG LLY MASI

Aug 7, 2025, 2:56 PM EDT - 2 months ago

Exact Sciences Dip A Chance To Buy As Freenome Deal Fortifies Future: Analyst

Aug 6, 2025, 11:11 PM EDT - 2 months ago

Exact Sciences Corporation (EXAS) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:05 PM EDT - 2 months ago

Exact Sciences Announces Second Quarter 2025 Results

Aug 6, 2025, 4:05 PM EDT - 2 months ago

Exact Sciences Announces Exclusive License with Freenome for Blood-Based Colorectal Cancer Screening Tests

Jul 31, 2025, 7:00 AM EDT - 3 months ago

Exact Sciences and Humana Expand Colorectal Cancer Screening Partnership with Cologuard Plus™ Test

Jul 14, 2025, 6:00 AM EDT - 3 months ago

Exact Sciences Schedules Second Quarter 2025 Earnings Call

Jul 10, 2025, 11:19 AM EDT - 3 months ago

Geneoscopy Wins Patent Trial and Appeal Board Decision, Invalidating All 20 Claims of Exact Sciences' '781 Patent

Jul 9, 2025, 6:00 AM EDT - 3 months ago

Exact Sciences Announces Medicare Coverage for Oncodetect™ Molecular Residual Disease Test in Colorectal Cancer

May 28, 2025, 6:05 AM EDT - 5 months ago

Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap

May 27, 2025, 4:05 PM EDT - 5 months ago

Exact Sciences to Participate in June Investor Conference

May 22, 2025, 5:05 PM EDT - 5 months ago

Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025

May 12, 2025, 10:00 AM EDT - 6 months ago

Exact Sciences Earns 2025 Great Place To Work® Certification™

May 2, 2025, 12:52 PM EDT - 6 months ago

Exact Sciences Q1 Earnings: Decent Quarter, But Growth Story Not Compelling

May 2, 2025, 9:18 AM EDT - 6 months ago

Cancer Diagnostic Firm Exact Sciences' CEO Says Strong Q1 Paves Way For 'Transformative' 2025, Lifts Annual Guidance

May 2, 2025, 6:00 AM EDT - 6 months ago

Exact Sciences to Participate in May Investor Conference

May 1, 2025, 8:47 PM EDT - 6 months ago

Exact Sciences Corporation (EXAS) Q1 2025 Earnings Call Transcript

May 1, 2025, 4:05 PM EDT - 6 months ago

Exact Sciences Announces First-Quarter 2025 Results

Apr 29, 2025, 6:59 AM EDT - 6 months ago

Exact Sciences to Highlight Cologuard® Test Adherence and Predicted Preference Data at Digestive Disease Week (DDW) 2025

Apr 22, 2025, 6:00 AM EDT - 6 months ago

Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test

Apr 14, 2025, 6:00 AM EDT - 7 months ago

JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups

Apr 1, 2025, 6:00 AM EDT - 7 months ago

Exact Sciences Schedules First Quarter 2025 Earnings Call

Mar 31, 2025, 6:00 AM EDT - 7 months ago

Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening

Mar 12, 2025, 9:00 AM EDT - 8 months ago

Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner

Mar 12, 2025, 5:00 AM EDT - 8 months ago

New Data Highlight the Positive Impact of Exact Sciences' Oncotype DX® Test on Patient Care and Healthcare Efficiency

Feb 24, 2025, 6:00 AM EST - 8 months ago

Exact Sciences to Participate in March Investor Conferences

Feb 24, 2025, 12:16 AM EST - 8 months ago

Exact Sciences: A Strong Q4 Reveals Signs Of A Potential Inflection Point

Feb 19, 2025, 8:37 PM EST - 8 months ago

Exact Sciences Corporation (EXAS) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 4:05 PM EST - 8 months ago

Exact Sciences Announces Fourth Quarter 2024 Results

Feb 18, 2025, 7:05 AM EST - 8 months ago

U.S. Patent Trial and Appeal Board Institutes Inter Partes Review Based on Geneoscopy's Petition Challenging Validity of a Second Patent Asserted by Exact Sciences

Feb 5, 2025, 8:00 AM EST - 9 months ago

Flatiron Health and Exact Sciences Partner to Advance Clinical Evidence Generation for Molecular Residual Disease Testing

Feb 3, 2025, 6:00 AM EST - 9 months ago

Exact Sciences Schedules Fourth Quarter 2024 Earnings Call

Jan 21, 2025, 5:05 PM EST - 9 months ago

Exact Sciences Demonstrates Leadership in Cancer Innovation with New Data on Screening and Molecular Residual Disease at 2025 ASCO GI Symposium

Jan 21, 2025, 5:05 PM EST - 9 months ago

New Evidence Validates Oncodetect's™ Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients

Jan 13, 2025, 1:04 PM EST - 10 months ago

Exact Sciences Sparks Analyst Optimism Amid Competitive Multi-Cancer Test Market

Jan 12, 2025, 7:00 PM EST - 10 months ago

Exact Sciences Announces Preliminary Fourth Quarter 2024 Results

Jan 2, 2025, 6:00 AM EST - 10 months ago

Exact Sciences to Participate in J.P. Morgan Healthcare Conference

Peace2016 Oct. 27 at 4:36 AM

$EXAS we are up 5% in overnight market!!

0 · Reply

LiquidThetaLEAPS Oct. 27 at 3:47 AM

0 · Reply

LiquidThetaLEAPS Oct. 26 at 5:47 AM

0 · Reply

Clargy Oct. 24 at 3:51 PM

$EXAS Eruption here soon

0 · Reply

LiquidThetaOptions Oct. 24 at 3:28 PM

0 · Reply

Kleeno Oct. 24 at 4:24 AM

0 · Reply

cc10socr Oct. 24 at 2:24 AM

$EXAS just broke even on this, fuck it and sell?

1 · Reply

ManyThanks212 Oct. 23 at 5:32 PM

$EXAS

0 · Reply

Estimize Oct. 23 at 2:30 PM

Wall St is expecting -0.04 EPS for $EXAS Q3 [Reporting 11/03 AMC] http://www.estimize.com/intro/exas?chart=historical&metric_name=eps&utm_c

0 · Reply

Thelonius_Stonk Oct. 22 at 4:01 PM

$EXAS so strong

1 · Reply

Woodman7 Oct. 22 at 2:24 PM

$EXAS - https://www.facebook.com/share/v/17NLhJhRKj/?mibextid=wwXIfr

1 · Reply

JarvisFlow Oct. 22 at 12:10 PM

BTIG has updated their rating for Exact Sciences ( $EXAS ) to Buy with a price target of 75.

0 · Reply

FloatTrip Oct. 21 at 3:07 AM

$EXAS Still undervalued. Still at a discount.

2 · Reply

THE_Monkey_Banana_Genius Oct. 20 at 7:56 PM

$GH $NTRA $EXAS long all these molecular diagnostics names

2 · Reply

LiquidThetaOptions Oct. 20 at 1:47 PM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $EXAS Current Share Price: $61.23 Contracts: $EXAS January 15, 2027 $62 Calls Scale in: $12.44- $15.20 Scale out: $19.35-$24.88 Can Easily Capture: 60% ROI Blended DTE: 453 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

Kleeno Oct. 20 at 2:00 AM

$EXAS Never seen trading taking place “overnight” on Yahoo!

0 · Reply

Kleeno Oct. 20 at 1:58 AM

$EXAS CancerGuard highlighted on GMA. https://abcnews.go.com/GMA/Wellness/video/maria-menounos-importance-early-cancer-detection-126577735

0 · Reply

Woodman7 Oct. 18 at 11:42 AM

He got an at-home colon cancer test in the mail. The problem? He doesn't have a colon. $EXAS https://www.usatoday.com/story/news/health/2025/10/12/why-colon-cancer-tests-mailed-to-homes/86192537007/

1 · Reply

LiquidThetaLEAPS Oct. 18 at 4:41 AM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $EXAS Current Share Price: $61.29 Contracts: $EXAS January 15, 2027 $62 Calls Scale in: $12.64- $15.44 Scale out: $19.66-$25.27 Can Easily Capture: 60% ROI Blended DTE: 455 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

MoneyGroupLLC Oct. 17 at 12:37 PM

Enter: $EXAS NOV 07 2025 $61 CALLS Buy in Price: $4.20 - $4.20 Take Profit: $5.46 Stop Bleeding: $3.70 ROI Potential: 30% Exit Within: 3 Weeks https://moneygroup.us/alerts

0 · Reply

Woodman7 Oct. 17 at 12:14 PM

$EXAS https://share.google/HpVDMwXgU4KkpPr5v

0 · Reply

Aaronpell Oct. 17 at 3:03 AM

$EXAS Cancerguard a sponsor of Good Morning America.

1 · Reply

Market Cap	12.24B
Revenue (ttm)	2.76B
Net Income (ttm)	-1.03B
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	172.93
Profit Margin	-37.29%
Debt to Equity Ratio	0.00

Volume	1,976,700
Avg Vol	2,457,732
Day's Range	N/A - N/A
Shares Out	189.32M
Stochastic %K	88%
Beta	1.24
Analysts	Strong Sell
Price Target	$70.35